New small molecule direct antiviral hepatitis C drugs, especially interferon-free hepatitis C regimens, have become a major research direction in the world for the treatment of hepatitis C. The most important and effective drug components in the world today are sofosbuvir (sofosbuvir) and daclatasvir (daclatasvir). In December 2013, the US FDA approved the second-generation direct antiviral drug sofosbuvir sofosbuvir, and in 2014, the European Medicines Agency (EMA) approved sofosbuvir and Schweppes’ daclatasvir daclatasvir. India approved the marketing of sofosbuvir sofosbuvir in 2014, and in May 2015, the Lao Ministry of Health approved the marketing of Sofeni Sofeni (sofosbuvir) and Dactinna Dactinna (daclatasvir) and designated the promotion of a hepatitis C prevention and treatment program at the Lao Friendship Hospital (Mittaphab Hospital). The new direct antiviral hepatitis C drugs (DAAs) act directly on the hepatitis C virus protease, RNA polymerase and other important aspects of viral replication, effectively achieving inhibition of viral replication and increasing the cure rate to more than 95 percent. The HCV RNA genome uses itself as the template for its own viral replication and provides viral messenger RNA for virion synthesis. The HCV RNA chromosome serves as the template for viral replication and the viral messenger RNA, which is cleaved by protease inhibitors and converted into a polyprotein. All HCV enzymes-NS2-3 and NS3-4A proteins, NS3 helicase, NS5A and NS5B polymerase steps in HCV replication become the main targets of new drugs. Sofosbuvir Sofosbuvir acts directly with NS5B and daclatasvir Daclatasvir acts directly on NS5A non-structural proteins. The combination of sofosbuvir and daclatasvir has the highest cure rate, broadest applicability and highest safety profile of new interferon-free direct antiviral hepatitis C regimens, according to the latest European Society of the Liver (EASL) 2015 Recommended Regimens for the Treatment of Hepatitis C 2015. The pan-genotypic nature of daclatasvir and its complete safety in the kidney make sofosbuvir and daclatasvir a broadly applicable regimen, especially for patients with refractory hepatitis C type 3, cirrhosis, decompensated disease and liver and kidney transplantation.